Core Viewpoint - A class action lawsuit has been filed against Treace Medical Concepts, Inc. for allegedly misleading investors about the demand for its primary product, the Lapiplasty 3D Bunion Correction System, leading to a significant decline in stock price [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Treace Medical failed to disclose competition affecting the demand for its primary product, resulting in a revenue decline [2]. - Following the revelation of these issues, Treace Medical's stock price dropped nearly 63%, closing at $4.17 per share on May 8, 2024 [2]. Group 2: Class Action Participation - Shareholders may be eligible to participate in the class action, with a deadline to file as lead plaintiff by June 10, 2025 [3]. - Shareholders can choose to remain absent class members without participating in the case [3]. Group 3: Company Background - Treace Medical Concepts, Inc. focuses on advancing surgical management standards for bunion and related midfoot deformities [1].

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Treace Medical Concepts, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers [1] Financial Performance - On May 7, 2024, Treace Medical lowered its full-year 2024 revenue guidance from a range of $220 million to $225 million down to a range of $201 million to $211 million [3] - The company's stock price fell by $6.95, nearly 63%, closing at $4.17 per share on May 8, 2024, following the revenue guidance revision [4] Competitive Landscape - The company reported that competition from minimally invasive osteotomy and Lapiplasty "knockoffs" has created headwinds for the growth of its Lapiplasty product [3]

NEW YORK, April 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Treace Medical Concepts, Inc. (NASDAQ: TMCI).Shareholders who purchased shares of TMCI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/treace-medical-concepts-inc-loss-submission-form-2/?id=143353&from=4CLASS ...

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Treace Medical Concepts, Inc. securities for the period between May 8, 2023, and May 7, 2024, due to alleged misleading statements and failure to disclose critical information regarding the company's primary product and its market performance [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Treace Medical's management made false and/or misleading statements about the demand for its Lapiplasty 3D Bunion Correction System, which led to a decline in revenue and necessitated an accelerated product development plan [5]. - The lawsuit alleges that the positive statements made by Treace Medical regarding its business operations and prospects were materially misleading and lacked a reasonable basis [5]. Group 2: Participation Information - Investors who purchased Treace Medical securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Treace Medical Concepts, Inc. (“Treace Medical” or “the Company”) (NASDAQ: TMCI) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise a ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Treace Medical To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Treace Medical between May 8, 2023, and May 7, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- ...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, April 16, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Treace Medical Concepts, Inc. ("Treace Medical" or the "Company") (NASDAQ: TMCI) investors of a class action representing investors that bought securities between May 8, 2023 and May 7, 2024, inclusive (the "Class Period"). Treace Medical investors have until June 10, 2025 to file a lead plaintiff motion. Investors are encouraged to contact at ...

Core Points - A class action has been filed against Treace Medical Concepts, Inc. for allegedly misleading investors regarding the demand for its primary product, the Lapiplasty 3D Bunion Correction System [1][2] - The complaint states that competition negatively impacted the demand and utilization of the Lapiplasty system, leading to a decline in Treace Medical's revenue [2] - Following the revelation of these issues, Treace Medical's stock price dropped nearly 63%, closing at $4.17 per share on May 8, 2024 [2] Company Overview - Treace Medical Concepts, Inc. focuses on advancing surgical management standards for bunion and related midfoot deformities [1] - The company is under scrutiny for its failure to disclose critical information regarding competition and product demand [2] Legal Proceedings - Shareholders interested in serving as lead plaintiffs must file their papers by June 10, 2025 [3] - Participation in the class action is not mandatory for recovery; shareholders can remain absent class members [3] Firm Background - Robbins LLP is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4]

Core Viewpoint - A class action lawsuit has been filed against Treace Medical Concepts, Inc. for alleged misleading statements and failure to disclose critical information regarding its primary product, the Lapiplasty 3D Bunion Correction System, impacting investor decisions during the specified Class Period [1][5]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of purchasers of Treace Medical securities between May 8, 2023, and May 7, 2024 [1]. - Allegations include that competition affected the demand for the Lapiplasty system, leading to a decline in revenue and necessitating an accelerated product development plan [5]. - The lawsuit claims that the defendants made materially misleading statements about the company's business and prospects, resulting in investor damages when the truth was revealed [5]. Group 2: Participation Information - Investors who purchased Treace Medical securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must file a motion with the court by June 10, 2025, to represent other class members [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, with notable achievements in previous years, including over $438 million in 2019 [4].

Core Viewpoint - A securities class action lawsuit has been filed against Treace Medical Concepts, Inc. for allegedly making false and misleading statements regarding its business operations and financial performance during the specified class period [1][2]. Company Summary - The lawsuit claims that Treace Medical failed to disclose significant competition affecting the demand for its primary product, the Lapiplasty 3D Bunion Correction System, leading to a decline in revenue [2]. - The company is accused of needing to accelerate plans to introduce an alternative product to osteotomy due to competitive pressures [2]. - Positive statements made by the company regarding its business prospects are alleged to be materially misleading [2]. Financial Impact - On May 7, 2024, Treace Medical reported its financial results, revealing that competition from minimally invasive osteotomy and Lapiplasty knockoffs hindered growth [3]. - Following this announcement, the company's stock price plummeted by $6.95, nearly 63%, closing at $4.17 per share on May 8, 2024, with unusually high trading volume [4].